Jennifer A. Woyach, MD, Discusses Previous Results of the AO41202 Trial Examining Ibrutinib Regimens in CLL

News
Video

Jennifer A. Woyach, MD, spoke about the phase 3 AO41202 study, which investigated different ibrutinib regimens for elderly patients with chronic lymphocytic leukemia.

During the 2021 American Society of Hematology Annual Meeting, Jennifer A. Woyach, MD, associate professor in the Division of Hematology at The Ohio State University, discussed previously reported results of the phase 3 AO41202 study (NCT01886872), which looked to treat patients over 65 years of age who had not received prior therapy with ibrutinib (Imbruvica) regimens or chemoimmunotherapy for chronic lymphocytic leukemia (CLL). Woyach discusses prior results in anticipation of updated data that will be presented at the meeting.

Transcript:

The AO41202 study is a National Clinical Trials Network [NCTN]-sponsored phase 3 trial led by the Alliance for Clinical Trials in Oncology. In this study, we looked at the optimal care of older patients with previously untreated CLL. This study is for patients who are age 65 or older who had not received prior CLL therapy. We randomized them 1:1:1 for treatment with bendamustine plus rituximab, or ibrutinib given alone or ibrutinib given in combination with rituximab. The primary results of the study showed that either regimen containing ibrutinib showed superior progression-free survival to bendamustine and rituximab, and there was no difference between the 2 ibrutinib containing regimens.

Reference

Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517-2528. doi:10.1056/NEJMoa1812836

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content